CKR 492
Alternative Names: CKR-492Latest Information Update: 31 Jul 2023
At a glance
- Originator CK Regeon
- Class Antidementias; Small molecules
- Mechanism of Action CXXC5 protein inhibitors; Wnt signalling pathway stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 24 Jul 2023 CK Regeon has patents pending for therapeutic compositions of agents inhibiting CXXC5-DV and methods of use in USA, South Korea, China, Europe, Japan and other countries
- 24 Jul 2023 Preclinical trials in Alzheimer's disease in South Korea (PO) before July 2023 (CK Regeon pipeline, July 2023)